30.08.18: Not intended for U.S. and UK Media

Bayer receives US approval for modern hemophilia A treatment Jivi® with a step-wise prophylaxis dosing regimenJivi's extended half-life allows for twice-weekly initial dosing / May be adjusted to every five days and further individually adjusted to less or more frequent dosingmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news